OMED a clinical-stage company presenting data in two posters, highlighting the company's translational research and biomarker efforts for its tarextumab. CELG announced that the (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for OTEZLA.

OncoMed has been noted in NFTRH as a “lottery ticket” hold over the last several week and today I am taking the 14% off the little bottoming pattern, which by the way, measures to 26+.

Since I considered the news that originally launched OMED to be fundamentally sound as opposed to hype, I’ve kept it on radar all these months. On Friday I saw it sitting at support and decided to take a shot.